BioPhorum members recognize the need to transform the performance of the global supply chain for biologics, and so a team of subject matter experts from across multiple companies are shaping a program of cross-industry collaboration to address topics ranging from capacity constraints, increased costs, and alignment on quality expectations of the outbound supply chain.
Lesley Holt, BioPhorum Supply Chain to Patient Director, discusses freight capacity and increased costs, complexity of supply chains for cell and gene therapy and direct to patient, and the benefits of collaboration on influencing regulations.
